Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny
Open Access
- 14 October 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (4), 321-338
- https://doi.org/10.3390/pharmaceutics2040321
Abstract
Significant drug-nutrient interactions are possible when drugs and nutrients share the same absorption and disposition mechanisms. During postnatal development, the outcomes of drug-nutrient interactions may change with postnatal age since these processes undergo ontogenesis through the postnatal period. Our study investigated the dependence of a significant drug-nutrient interaction (cefepime-carnitine) on the timing and duration of drug exposure relative to postnatal age. Rat pups were administered cefepime (5 mg/kg) twice daily subcutaneously according to different dosing schedules (postnatal day 1-4, 1-8, 8-11, 8-20, or 1-20). Cefepime significantly reduced serum and heart L-carnitine levels in postnatal day 1-4, 1-8 and 8-11 groups and caused severe degenerative changes in ventricular myocardium in these groups. Cefepime also altered the ontogeny of several key L-carnitine homeostasis pathways. The qualitative and quantitative changes in levels of hepatic γ-butyrobetaine hydroxylase mRNA and activity, hepatic trimethyllysine hydroxlase mRNA, intestinal organic cation/carnitine transporter (Octn) mRNA, and renal Octn2 mRNA depended on when during postnatal development the cefepime exposure occurred and duration of exposure. Despite lower levels of heart L-carnitine in earlier postnatal groups, levels of carnitine palmitoyltransferase mRNA and activity, heart Octn2 mRNA and ATP levels in all treatment groups remained unchanged with cefepime exposure. However, changes in other high energy phosphate substrates were noted and reductions in the phosphocreatine/ATP ratio were found in rat pups with normal serum L-carnitine levels. In summary, our data suggest a significant drug-nutrient transport interaction in developing neonates, the nature of which depends on the timing and duration of exposure relative to postnatal age.This publication has 54 references indexed in Scilit:
- Carnitine homeostasis, mitochondrial function and cardiovascular diseaseDrug Discovery Today: Disease Mechanisms, 2009
- Cardiomyopathy and carnitine deficiencyMolecular Genetics and Metabolism, 2008
- A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levelsAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Effect of Carnitine Deprivation on Carnitine Homeostasis and Energy Metabolism in Mice with Systemic Carnitine DeficiencyAnnals of Nutrition and Metabolism, 2008
- Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic ConsiderationsClinical Pharmacokinetics, 2006
- TISSUE DISTRIBUTION AND ONTOGENY OF ORGANIC CATION TRANSPORTERS IN MICEDrug Metabolism and Disposition, 2005
- L-Carnitine Regulates mRNA Expression Levels of the Carnitine Acyltransferases – CPT1A, CPT2, and CRATMonatshefte für Chemie / Chemical Monthly, 2005
- Nutrient Regulation of the Intestinal Na+/Glucose Co-Transporter (SGLT1) Gene ExpressionBiochemical and Biophysical Research Communications, 1997
- EditorialBritish Journal of Nutrition, 1989
- The development of carnitine synthesis from γ-butyrobetaine in the ratLife Sciences, 1981